パイロプトーシス阻害剤としてのピクロシドII封入ナノ製剤は,サイトカインストームを緩和し,腸内微生物群の障害を再構成する
Qian Wu1,2, A-Ling Tang1,2, Qing-Qing Dong1,2
1Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P. R. China.
ACS nano
|September 1, 2025
まとめ
この研究では,熱中症を抑制し,腸内微生物群を回復させることで,新種のナノ製剤を開発しました. この新しい治療法は 炎症や臓器損傷を効果的に軽減し 治療戦略として有望です
科学分野:
- バイオメディカルエンジニアリング
- ナノテクノロジー
- 免疫学
背景:
- セプシスは主要な死因であり,ピロプトーシス,サイトカイン放出症候群,腸内不活性症によって特徴付けられます.
- セプシスの現在の治療は,しばしば反応性酸素種 (ROS) / NOD型の受容体ピリンドメイン含有3 (NLRP3) / カスペーゼ-1経路を標的とするが,リポポリサカリド (LPS) 誘発のピロプトーシスを標的とするわけではない.
- 腸内微生物群の障害はセプシスの進行と二次サイトカインストームにおいて重要な役割を果たしますが,治療評価ではしばしば見過ごされます.
研究 の 目的:
- セプシス治療のピロプトーシス調節剤として,ピクロシドIIで封じ込められたパルミチン酸調製ナノ製剤を開発する.
- リポポリサカリド (LPS) 誘発のピロプトーシスとサイトカイン放出症候群を抑制するナノ製剤の能力を調査する.
- 腸内微生物群の構成と腸内バリア機能に対するナノ製剤の影響を評価する.
主な方法:
- パルミチン酸で改造されたピクロシドIIのナノ製剤の調製
- トール型受容体媒介によるナノ粒子細胞吸収の評価.
- 抗酸化剤,抗炎症剤,および抗炎症症剤の評価 in vitro および in vivo.
- ピロプトーシスに関連するタンパク質レベルと炎症因子の分析
- 腸内細菌の組成と腸内バリア機能の変化の調査
主要な成果:
- パルミチ酸の改変により,Tollのような受容体の認識により,ナノ粒子の細胞吸収が強化された.
- ピクロサイドIIの持続的な放出は,反応性酸素種 (ROS) を効果的に取り除き,炎症因子を減少させ,ピロプトーシスタンパク質を低下させました.
- ナノ製剤は,対照群と比較して優れた抗酸化,抗炎症,および抗炎症作用を示した.
- 治療により,LPSによる多臓器損傷,特に腎臓と大腸の損傷が軽減されました.
- ナノ製剤は腸内細菌の豊富さを改善し,腸内バリア機能を強化し,免疫システムを強化しました.
結論:
- パルミチン酸を添加した,ピクロシドIIで封じ込められたナノ製剤は,新種のセプシス治療戦略を表しています.
- これらのナノ製剤は,LPSによって引き起こされる熱死を効果的に抑制し,全身の炎症を軽減し,臓器の損傷を軽減します.
- 治療は腸内微生物群を正面的に調節し,全体的な治療効果と免疫ホメオスタシスの改善に貢献します.
関連する概念動画
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
01:29Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
01:17Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
01:30Inflammatory Bowel Disease II: Crohn's Disease
375
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
375
01:30Acute Pancreatitis II: Clinical Manifestations and Management
175
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
175
01:29Chronic Pancreatitis II: Collaborative Care
128
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
128